IRIS Accounts Production v23.3.1.45 12588498 director 1.4.22 31.3.23 31.3.23 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh125884982022-03-31125884982023-03-31125884982022-04-012023-03-31125884982021-03-31125884982021-04-012022-03-31125884982022-03-3112588498ns10:Originalns15:EnglandWales2022-04-012023-03-3112588498ns14:PoundSterlingns10:Original2022-04-012023-03-3112588498ns10:Originalns10:Director12022-04-012023-03-3112588498ns10:Original2022-04-012023-03-3112588498ns10:Original2023-03-3112588498ns10:Originalns10:PrivateLimitedCompanyLtd2022-04-012023-03-3112588498ns10:Originalns10:SmallEntities2022-04-012023-03-3112588498ns10:Originalns10:AuditExempt-NoAccountantsReport2022-04-012023-03-3112588498ns10:Originalns10:SmallCompaniesRegimeForDirectorsReport2022-04-012023-03-3112588498ns10:SmallCompaniesRegimeForAccountsns10:Original2022-04-012023-03-3112588498ns10:Originalns10:FullAccounts2022-04-012023-03-3112588498ns10:Original12022-04-012023-03-3112588498ns10:CompanySecretary1ns10:Original2022-04-012023-03-3112588498ns10:Originalns10:RegisteredOffice2022-04-012023-03-3112588498ns10:Original2022-03-3112588498ns10:Originalns5:CurrentFinancialInstruments2023-03-3112588498ns10:Originalns5:CurrentFinancialInstruments2022-03-3112588498ns10:Originalns5:Non-currentFinancialInstruments2023-03-3112588498ns10:Originalns5:Non-currentFinancialInstruments2022-03-3112588498ns5:ShareCapitalns10:Original2023-03-3112588498ns5:ShareCapitalns10:Original2022-03-3112588498ns10:Originalns5:RetainedEarningsAccumulatedLosses2023-03-3112588498ns10:Originalns5:RetainedEarningsAccumulatedLosses2022-03-3112588498ns10:Originalns5:NetGoodwill2022-04-012023-03-3112588498ns5:IntangibleAssetsOtherThanGoodwillns10:Original2022-04-012023-03-3112588498ns10:Original2021-04-012022-03-3112588498ns10:Originalns5:NetGoodwill2022-03-3112588498ns10:Originalns5:NetGoodwill2023-03-3112588498ns10:Originalns5:NetGoodwill2022-03-3112588498ns10:Originalns5:LandBuildings2022-03-3112588498ns10:Originalns5:FurnitureFittings2022-03-3112588498ns10:Original2022-03-3112588498ns10:Originalns5:LandBuildings2022-04-012023-03-3112588498ns10:Originalns5:FurnitureFittings2022-04-012023-03-3112588498ns10:Originalns5:LandBuildings2023-03-3112588498ns10:Originalns5:FurnitureFittings2023-03-3112588498ns10:Originalns5:LandBuildings2022-03-3112588498ns10:Originalns5:FurnitureFittings2022-03-3112588498ns10:Originalns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-03-3112588498ns10:Originalns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-03-31
REGISTERED NUMBER: 12588498 (England and Wales)















REAL PHARMA SOLUTIONS LTD

UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2023






REAL PHARMA SOLUTIONS LTD (REGISTERED NUMBER: 12588498)

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31ST MARCH 2023










Page

Company Information 1

Balance Sheet 2 to 3

Notes to the Financial Statements 4 to 6


REAL PHARMA SOLUTIONS LTD

COMPANY INFORMATION
FOR THE YEAR ENDED 31ST MARCH 2023







DIRECTOR: R George





SECRETARY: S Robin





REGISTERED OFFICE: 7 Jardine House
Harrovian Business Village
Bessborough Road
Harrow
HA1 3EX





REGISTERED NUMBER: 12588498 (England and Wales)





ACCOUNTANTS: TG Associates Limited
Chartered Accountants
7 Jardine House
Harrovian Business Village
Bessborough Road
Harrow
Middlesex
HA1 3EX

REAL PHARMA SOLUTIONS LTD (REGISTERED NUMBER: 12588498)

BALANCE SHEET
31ST MARCH 2023

31.3.23 31.3.22
Notes £    £   
FIXED ASSETS
Intangible assets 4 545,796 545,796
Tangible assets 5 311,241 297,534
857,037 843,330

CURRENT ASSETS
Stocks 25,255 30,950
Debtors 6 121,449 100,864
Cash at bank and in hand 232,967 172,602
379,671 304,416
CREDITORS
Amounts falling due within one year 7 (394,375 ) (376,114 )
NET CURRENT LIABILITIES (14,704 ) (71,698 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

842,333

771,632

CREDITORS
Amounts falling due after more than one
year

8

(632,099

)

(663,524

)
NET ASSETS 210,234 108,108

CAPITAL AND RESERVES
Called up share capital 1,000 1,000
Retained earnings 209,234 107,108
210,234 108,108

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st March 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31st March 2023 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

REAL PHARMA SOLUTIONS LTD (REGISTERED NUMBER: 12588498)

BALANCE SHEET - continued
31ST MARCH 2023


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 17th November 2023 and were signed by:





R George - Director


REAL PHARMA SOLUTIONS LTD (REGISTERED NUMBER: 12588498)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31ST MARCH 2023


1. STATUTORY INFORMATION

Real Pharma Solutions Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 2021, is being amortised evenly over its estimated useful life of nil years.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Tangible fixed assets
Depreciation is provided at the following rates in order to write off each asset over its estimated useful life.

Fixtures and fittings - 20% on cost

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

REAL PHARMA SOLUTIONS LTD (REGISTERED NUMBER: 12588498)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31ST MARCH 2023


2. ACCOUNTING POLICIES - continued

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 6 (2022 - 5 ) .

4. INTANGIBLE FIXED ASSETS
Goodwill
£   
COST
At 1st April 2022
and 31st March 2023 545,796
NET BOOK VALUE
At 31st March 2023 545,796
At 31st March 2022 545,796

5. TANGIBLE FIXED ASSETS
Fixtures
Freehold and
property fittings Totals
£    £    £   
COST
At 1st April 2022 252,000 45,534 297,534
Additions - 28,517 28,517
At 31st March 2023 252,000 74,051 326,051
DEPRECIATION
Charge for year - 14,810 14,810
At 31st March 2023 - 14,810 14,810
NET BOOK VALUE
At 31st March 2023 252,000 59,241 311,241
At 31st March 2022 252,000 45,534 297,534

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.23 31.3.22
£    £   
Trade debtors 95,948 81,422
Other debtors 25,501 19,442
121,449 100,864

REAL PHARMA SOLUTIONS LTD (REGISTERED NUMBER: 12588498)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31ST MARCH 2023


7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.23 31.3.22
£    £   
Trade creditors 125,003 132,677
Taxation and social security 58,848 24,986
Other creditors 210,524 218,451
394,375 376,114

8. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
31.3.23 31.3.22
£    £   
Bank loans 632,099 663,524

Amounts falling due in more than five years:

Repayable by instalments
Bank loans more 5 yr by instal 632,099 663,524